Ocular Therapeutix (OCUL) Getting Somewhat Favorable Media Coverage, Accern Reports
News articles about Ocular Therapeutix (NASDAQ:OCUL) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocular Therapeutix earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.346096727115 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the headlines that may have effected Accern’s analysis:
- Insider Buying: Ocular Therapeutix, Inc. (OCUL) Insider Purchases 21,000 Shares of Stock (americanbankingnews.com)
- Ocular Therapeutix, Inc. (OCUL) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
- Ocular Therapeutix, Inc. (OCUL) CFO Donald Notman Purchases 4,800 Shares (americanbankingnews.com)
- Daniel M. Bollag Buys 24,700 Shares of Ocular Therapeutix, Inc. (OCUL) Stock (americanbankingnews.com)
- Financial Contrast: Ocular Therapeutix (OCUL) vs. Capnia (SLNO) (americanbankingnews.com)
Shares of Ocular Therapeutix (NASDAQ:OCUL) traded up $0.42 during trading on Thursday, hitting $4.69. 389,000 shares of the stock traded hands, compared to its average volume of 855,936. The company has a current ratio of 4.79, a quick ratio of 4.78 and a debt-to-equity ratio of 0.39. Ocular Therapeutix has a 1 year low of $3.30 and a 1 year high of $11.79.
Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. The company had revenue of $523.00 million during the quarter, compared to analyst estimates of $0.52 million. During the same quarter last year, the firm posted ($0.39) earnings per share. The firm’s revenue was up 9.6% on a year-over-year basis. analysts predict that Ocular Therapeutix will post -2.37 EPS for the current year.
A number of brokerages have commented on OCUL. ValuEngine cut shares of Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research report on Monday, September 25th. Guggenheim began coverage on shares of Ocular Therapeutix in a research report on Monday, October 23rd. They set a “buy” rating and a $12.00 price target on the stock. Zacks Investment Research cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $20.67.
In other news, insider Antony C. Mattessich acquired 21,000 shares of the stock in a transaction on Tuesday, December 12th. The stock was acquired at an average price of $4.29 per share, with a total value of $90,090.00. Following the completion of the transaction, the insider now owns 21,000 shares of the company’s stock, valued at approximately $90,090. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Amarpreet Sawhney acquired 19,000 shares of the stock in a transaction on Thursday, November 16th. The shares were purchased at an average cost of $5.18 per share, with a total value of $98,420.00. Following the transaction, the chairman now directly owns 696,390 shares of the company’s stock, valued at approximately $3,607,300.20. The disclosure for this purchase can be found here. Insiders purchased 69,500 shares of company stock valued at $304,781 in the last ninety days. 26.10% of the stock is currently owned by insiders.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with Analyst Ratings Network's FREE daily email newsletter.